Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Meningococcal ACWY Polysaccharide Vaccine · 1 trial · 2 indications
Safety of the Novartis MenACWY conjugate vaccine and of a licensed meningococcal ACWY conjugate vaccine as measured by the number of subjects presenting at least one severe systemic reaction during the first 7 days following a single vaccination in healthy subjects.
| Arm | Type | Description |
|---|---|---|
| Novartis MenACWY Vaccine (19 to 55 Years) | EXPERIMENTAL | Novartis meningococcal ACWY conjugate vaccine administered to subjects 19 years to 55 years |
| Licensed polysaccharide vaccine | ACTIVE_COMPARATOR | Licensed meningococcal ACWY polysaccharide vaccine |
| Licensed Conjugate Vaccine | ACTIVE_COMPARATOR | Licensed meningococcal ACWY polysaccharide-protein conjugate vaccine |
| Novartis MenACWY Vaccine (56 to 65 Years) | EXPERIMENTAL | Novartis meningococcal ACWY conjugate vaccine administered to subjects 56 years to 65 years |
| Name | Type | Description |
|---|---|---|
| Meningococcal ACWY Polysaccharide Vaccine | BIOLOGICAL | One dose of the licensed meningococcal ACWY polysaccharide vaccine was administered by subcutaneous injection. |
| MenACWY CRM (19 to 55 years) | BIOLOGICAL | One dose of the Novartis meningococcal ACWY conjugate vaccine was administered by intramuscular injection to subjects 19 years to 55 years of age. |
| Meningococcal ACWY Conjugate Vaccine | BIOLOGICAL | One dose of the licensed meningococcal ACWY polysaccharide-protein conjugate vaccine was administered by intramuscular injection. |
| Novartis MenACWY Vaccine (56 to 65 Years) | BIOLOGICAL | One dose of the Novartis meningococcal ACWY conjugate vaccine was administered by intramuscular injection administered to subjects 56 years to 65 years of age. |
Inclusion Criteria: * individuals who are 19-65 years of age inclusive and who, after the nature of the study has been explained have provided written informed consent * individuals who are available for all visits and telephone calls scheduled for the study; * individuals who are in good health E...
Meningococcal ACWY Polysaccharide Vaccine is used for the prevention of meningococcal meningitis and meningococcal infections. It is an investigational vaccine being developed by Novartis AG for use in healthy adults. The vaccine is designed to provide immune response against the ACWY serogroups of the meningococcal bacteria.
Meningococcal ACWY Polysaccharide Vaccine is being developed by Novartis AG, a multinational pharmaceutical company. The company's stock is traded under the ticker symbol NVS. The vaccine is currently in Phase 3 clinical development for the prevention of meningococcal meningitis.
Meningococcal ACWY Polysaccharide Vaccine is in Phase 3 clinical development. It is an investigational vaccine and has not yet been approved by regulatory authorities. The Phase 3 trial has been completed, and the vaccine is being studied for its safety and immune response in healthy adults.
Meningococcal ACWY Polysaccharide Vaccine has one completed Phase 3 clinical trial with the identifier NCT00474487. The trial, titled 'A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Healthy Adults,' enrolled 2,831 participants in Argentina and Colombia. The study was randomized, double-blind, and active-controlled.
Meningococcal ACWY Polysaccharide Vaccine is a polysaccharide vaccine that works by stimulating the immune system to produce antibodies against the A, C, W, and Y serogroups of Neisseria meningitidis, the bacteria that cause meningococcal meningitis. This immune response helps protect against meningococcal infections.
Meningococcal ACWY Polysaccharide Vaccine is a vaccine targeting the same serogroups as other MenACWY vaccines, but it is a distinct investigational product developed by Novartis AG. It is not the same as other commercially available MenACWY vaccines, as it is still in clinical development and has not been approved.